Brief reports
No clinically important effects on intraocular pressure after short-term administration of sildenafil citrate (Viagra)

https://doi.org/10.1016/S0002-9394(00)00375-5Get rights and content

Abstract

PURPOSE: To assess the short-term effects of sildenafil citrate on intraocular pressure in healthy male volunteers and participants in clinical trials.

METHODS: Intraocular pressure and pupil diameter were measured in two placebo-controlled studies. Oral doses of sildenafil citrate (VIAGRA; Pfizer Inc, New York, New York) ranged from 10 mg to 150 mg.

RESULTS: No major changes in intraocular pressure or pupillometry were detected at any time (1.0–24 hours) after administration of sildenafil. Additionally, of 36 subjects with a medical history of increased intraocular pressure in the sildenafil safety database, none were reported to have a clinically significant increase of their intraocular pressure. During clinical trials, two glaucoma cases were listed as serious adverse events, but were not considered treatment related.

CONCLUSION: No clinical abnormalities were observed in intraocular pressure or pupil diameter in subjects receiving sildenafil. Currently, no evidence suggests that long-term treatment with sildenafil has an effect on intraocular pressure or is associated with the development or worsening of glaucoma.

References (6)

There are more references available in the full text version of this article.

Cited by (0)

This study is supported by Pfizer Inc. Drs Yajima and Yajima conducted the clinical trials for Pfizer. Drs Grunwald and Laties have served as consultants to Pfizer.

View full text